Summary
N4-Palmitoyl-1-β-D-arabinofuranosylcytosine (PLAC) was administered PO to 76 patients with acute leukemia, myelodysplastic syndromes (MDSs), and myeloproliferative disorders (MPDs). Of 20 patients with acute myelogenous leukemia, 2 achieved complete remission, and the only patient with acute lymphoblastic leukemia achieved partial remission. Remission was reached with PLAC 100–300 mg/day 25–66 days after the start of therapy. Among 22 patients with MDS, 1 patient achieved a good response and 8 achieved partial response. Responses were reached with PLAC 50–200 mg/day 7–153 days (median, 33 days) after the start of therapy. Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis. An antileukemia effect was noted in 1 of 5 with chronic myelogenous leukemia. Major side effects were gastrointestinal toxicities and myelosupression. In spite of the disadvantages, such as unpredictable absorption and a lower response rate to acute leukemia compared with its parent compound, this antileukemia Ara-C analogue that is administrable PO will be useful in the treatment of MDSs and MPDs, which do not necessarily require admission to hospital, and in the treatment of acute leukemia of the aged, a condition for which intensive chemotherapy is not appropriate.
Similar content being viewed by others
References
Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J, Ishida T, Kobayashi H (1976) Antitumor activity of newly synthesized N 4-acyl-β-D-arabinofuranosylcytosine. Cancer Res 36: 2726–2732
Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J, Kobayashi H (1977) N 4-Behenoyl-β-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 37: 2481–2486
Ellison RR, Holland JF, Weil M, Jacquilart C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT, Karanas A, Cuttner J, Spurr CL, Hays DM, Blom J, Leone LA, Haurani F, Kyle R, Hutchinson JL, Forcher J, Moon JH (1968) Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32: 507–523
Foon KA, Gale RP (1982) Controversies in the therapy of acute myelogenous leukemia. Am J Med 72: 963–979
Hori K, Tsuruo T, Nagamura K, Tsukagoshi S, Sakurai Y (1984) Antitumor effects and pharmacology of orally administered N 4-palmitoyl-1-β-D-arabinofuranosylcytosine in mice. Cancer Res 44: 172–177
Kimura K, Ohno R, Amaki I, Hattori K, Hirota Y, Hoshino A, Ichimaru M, Ito M, Kimura I, Maekawa T, Masaoka T, Nakamura T, Ogawa M, Oguro M, Ohta K, Osamura S, Shimoyama M, Takaku F, Uzuka Y, Yamada K (1985) Treatment of acute myelogenous leukemia in adults with N 4-behenoyl-β-D-arabinofuranosylcytosine. Cancer 56: 1913–1917
Kimura K, Ohno R, Amaki I, Hattori K, Hirota Y, Hoshino A, Ichimaru M, Ito M, Kimura I, Maekawa T, Massaoka T, Nakamura T, Ogawa M, Oguro M, Ohta K, Osamura S, Shimoyama M, Takaku F, Uzuka Y, Yamada K (1986) Phase I clinical and pharmacokinetic study of N 4-palmitoyl-1-β-D-arabinofuranosylcytosine (in preparation)
Lister TA, Rohatiner AZS (1982) The treatment of acute myelogenous leukemia in adults. Semin Hematol 19: 172–192
Tricot G, DeBock R, Denker AW, Boogaerts MA, Peterman M, Punt K, Verwilghen RL (1984) Low-dose cytosine arabinoside (Ara C) in myelodysplastic syndromes. Br J Haematol 58: 231–240
Wisch JS, Griggin JD, Kufe DW (1983) Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. N Engl J Med 309: 1599–1602
Yamada K, Kawashima K, Kato Y, Morishima Y, Ohno R (1980) Pharmacology and clinical studies of N 4-behenoyl-β-D-arabinofuranosylcytosine. Recent Results Cancer Res 70: 219–229
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Ohno, R., Hirano, M., Yamagata, K. et al. Treatment of leukemia and myelodysplastic syndromes with orally administered N4-palmitoyl-l-β-D-arabinofuranosylcytosine. Cancer Chemother. Pharmacol. 17, 161–164 (1986). https://doi.org/10.1007/BF00306747
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00306747